{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T22:14:18Z","timestamp":1783203258970,"version":"3.54.6"},"reference-count":68,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","funder":[{"name":"NIH","award":["R01-DC12519"],"award-info":[{"award-number":["R01-DC12519"]}]},{"name":"NIH","award":["R01-DC14942"],"award-info":[{"award-number":["R01-DC14942"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Progressive apraxia of speech (PAOS) is a neurodegenerative disorder most commonly arising from a 4-repeat tauopathy that affects the programming or planning of speech, although many patients develop a Parkinson-plus syndrome. The role of neuroinflammation as a disease mechanism is unknown. We investigated the spatial pattern of neuroinflammation in PAOS using PET and evaluated whether it is associated with disease severity, presence of Parkinson-plus features, and tau PET uptake.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods:<\/jats:title>\n            <jats:p>Twenty-five PAOS patients (13 with Parkinson-plus features) and 30 controls underwent inflammatory <jats:sup>11<\/jats:sup>C-ER176 and tau <jats:sup>18<\/jats:sup>F-flortaucipir PET scans as well as detailed clinical assessments. Multiple linear regression analyses compared the inflammatory standardized uptake value ratio (SUVR) between PAOS and controls and assessed the relationship with clinical test scores. Pearson correlation analysis examined the relationship between inflammatory and tau SUVRs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>PAOS had greater neuroinflammatory SUVR than controls in the precentral, supplementary motor area, frontal gyri, putamen, pallidum, subthalamic nucleus, and red nucleus (adjusted <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). Greater neuroinflammation was associated with worse parkinsonism, and patients who had developed Parkinson-plus features showed a broader pattern of neuroinflammation, extending to prefrontal, temporal and parietal cortices. Neuroinflammation correlated with tau uptake in most (96%) PAOS patients (<jats:italic toggle=\"yes\">r<\/jats:italic> &gt; 0.3, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05). The higher correlation was associated with worse parkinsonism (<jats:italic toggle=\"yes\">r<\/jats:italic> = 0.61, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05) and disease severity (<jats:italic toggle=\"yes\">r<\/jats:italic> = 0.54, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.05).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>\n                                 <jats:sup>11<\/jats:sup>C-ER176 PET analysis demonstrates neuroinflammation in frontal and subcortical regions in PAOS which is particularly severe and widespread with the development of Parkinson-plus clinical features. The colocalization of neuroinflammation and tau may support a relationship between these disease mechanisms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000005962","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:01:29Z","timestamp":1751299289000},"page":"731-742","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Distinct 11C-ER176 PET Neuroinflammatory Profiles and Tau Colocalization in Progressive Apraxia of Speech With and Without Parkinson-plus Syndrome"],"prefix":"10.1097","volume":"50","author":[{"given":"Ryota","family":"Satoh","sequence":"first","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-1302","authenticated-orcid":false,"given":"Rene L.","family":"Utianski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-3432","authenticated-orcid":false,"given":"Joseph R.","family":"Duffy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-0084","authenticated-orcid":false,"given":"Heather M.","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehkyoung C.","family":"Stephens","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyeon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Radiology"},{"name":"Department of Biomedical Engineering, College of Medicine, Hanyang University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2691-5757","authenticated-orcid":false,"given":"Matt","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-0863","authenticated-orcid":false,"given":"Rosa","family":"Rademakers","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mayo Clinic, Jacksonville, FL"},{"name":"VIB Center for Molecular Neurology, University of Antwerp, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-1667","authenticated-orcid":false,"given":"Val J.","family":"Lowe","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2930-8634","authenticated-orcid":false,"given":"Keith A.","family":"Josephs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Whitwell","sequence":"additional","affiliation":[{"name":"Department of Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"R1-20250630","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1080\/02687038.2020.1787732","article-title":"Primary progressive apraxia of speech: from recognition to diagnosis and care","volume":"35","author":"Duffy","year":"2021","journal-title":"Aphasiology"},{"key":"R2-20250630","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/brain\/aws032","article-title":"Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech","volume":"135","author":"Josephs","year":"2012","journal-title":"Brain"},{"key":"R3-20250630","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","article-title":"Classification of primary progressive aphasia and its variants","volume":"76","author":"Gorno-Tempini","year":"2011","journal-title":"Neurology"},{"key":"R4-20250630","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1038\/s41467-021-23687-8","article-title":"A molecular pathology, neurobiology, biochemical, genetic and neuroimaging study of progressive apraxia of speech","volume":"12","author":"Josephs","year":"2021","journal-title":"Nat Commun"},{"key":"R5-20250630","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/brain\/awl078","article-title":"Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech","volume":"129","author":"Josephs","year":"2006","journal-title":"Brain"},{"key":"R6-20250630","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/brain\/awu223","article-title":"The evolution of primary progressive apraxia of speech","volume":"137","author":"Josephs","year":"2014","journal-title":"Brain"},{"key":"R7-20250630","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/mdc3.12796","article-title":"An evaluation of the progressive supranuclear palsy speech\/language variant","volume":"6","author":"Whitwell","year":"2019","journal-title":"Mov Disord Clin Pract"},{"key":"R8-20250630","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2020.09.039","article-title":"The evolution of parkinsonism in primary progressive apraxia of speech: a 6-year longitudinal study","volume":"81","author":"Seckin","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"R9-20250630","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.1007\/s00415-024-12344-x","article-title":"Progression to corticobasal syndrome: a longitudinal study of patients with nonfluent primary progressive aphasia and primary progressive apraxia of speech","volume":"271","author":"Garcia-Guaqueta","year":"2024","journal-title":"J Neurol"},{"key":"R10-20250630","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fphar.2019.01008","article-title":"Neuroinflammation as a common feature of neurodegenerative disorders","volume":"10","author":"Guzman-Martinez","year":"2019","journal-title":"Front Pharmacol"},{"key":"R11-20250630","doi-asserted-by":"crossref","first-page":"6198","DOI":"10.1093\/hmg\/ddv336","article-title":"Tau deposition drives neuropathological, inflammatory and behavioral abnormalities independently of neuronal loss in a novel mouse model","volume":"24","author":"Cook","year":"2015","journal-title":"Hum Mol Genet"},{"key":"R12-20250630","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron"},{"key":"R13-20250630","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13024-017-0192-x","article-title":"Glial contributions to neurodegeneration in tauopathies","volume":"12","author":"Leyns","year":"2017","journal-title":"Mol Neurodegener"},{"key":"R14-20250630","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.3390\/ijms20133161","article-title":"Recent developments in TSPO PET imaging as a biomarker of neuroinflammation in neurodegenerative disorders","volume":"20","author":"Werry","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R15-20250630","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1038\/s41467-023-40937-z","article-title":"Translocator protein is a marker of activated microglia in rodent models but not human neurodegenerative diseases","volume":"14","author":"Nutma","year":"2023","journal-title":"Nat Commun"},{"key":"R16-20250630","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/mds.20668","article-title":"In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy","volume":"21","author":"Gerhard","year":"2006","journal-title":"Mov Disord"},{"key":"R17-20250630","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/mds.28395","article-title":"In vivo assessment of neuroinflammation in 4-repeat tauopathies","volume":"36","author":"Palleis","year":"2021","journal-title":"Mov Disord"},{"key":"R18-20250630","doi-asserted-by":"crossref","first-page":"e1989","DOI":"10.1212\/WNL.0000000000005610","article-title":"[(11)C] PK11195 binding in Alzheimer disease and progressive supranuclear palsy","volume":"90","author":"Passamonti","year":"2018","journal-title":"Neurology"},{"key":"R19-20250630","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/ana.25911","article-title":"Neuroinflammation and tau colocalize in vivo in progressive supranuclear palsy","volume":"88","author":"Malpetti","year":"2020","journal-title":"Ann Neurol"},{"key":"R20-20250630","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1038\/s41380-023-02188-8","article-title":"Individual regional associations between A\u03b2-, tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies","volume":"28","author":"Finze","year":"2023","journal-title":"Mol Psychiatry"},{"key":"R21-20250630","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/ene.12004","article-title":"Neuroimaging comparison of primary progressive apraxia of speech and progressive supranuclear palsy","volume":"20","author":"Whitwell","year":"2013","journal-title":"Eur J Neurol"},{"key":"R22-20250630","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","author":"Kreisl","year":"2020","journal-title":"Lancet Neurol"},{"key":"R23-20250630","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13550-017-0334-8","article-title":"Comparison of four 11C-labeled PET ligands to quantify translocator protein 18 kDa (TSPO) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176\u2014based on recent publications that measured specific-to-non-displaceable ratios","volume":"7","author":"Fujita","year":"2017","journal-title":"EJNMMI Res"},{"key":"R24-20250630","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2967\/jnumed.116.178996","article-title":"11C-ER176, a radioligand for 18-kDa translocator protein, has adequate sensitivity to robustly image all three affinity genotypes in human brain","volume":"58","author":"Ikawa","year":"2017","journal-title":"J Nucl Med"},{"key":"R25-20250630","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-019-04349-w","article-title":"Head-to-head comparison of (11)C-PBR28 and (11)C-ER176 for quantification of the translocator protein in the human brain","volume":"46","author":"Zanotti-Fregonara","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-20250630","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e31829c5ed5","article-title":"Syndromes dominated by apraxia of speech show distinct characteristics from agrammatic PPA","volume":"81","author":"Josephs","year":"2013","journal-title":"Neurology"},{"key":"R27-20250630","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","article-title":"Prevalence of biologically vs clinically defined alzheimer spectrum entities using the national institute on aging-Alzheimer\u2019s association research framework","volume":"76","author":"Jack","year":"2019","journal-title":"JAMA Neurol"},{"key":"R28-20250630","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3233\/JAD-230912","article-title":"Amyloid and tau PET positivity in progressive agrammatic aphasia and apraxia of speech","volume":"96","author":"Tetzloff","year":"2023","journal-title":"J Alzheimers Dis"},{"key":"R29-20250630","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1093\/brain\/awz157","article-title":"Progressive agrammatic aphasia without apraxia of speech as a distinct syndrome","volume":"142","author":"Tetzloff","year":"2019","journal-title":"Brain"},{"key":"R30-20250630","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/mds.26987","article-title":"Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria","volume":"32","author":"Hoglinger","year":"2017","journal-title":"Mov Disord"},{"key":"R31-20250630","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1212\/WNL.0b013e31827f0fd1","article-title":"Criteria for the diagnosis of corticobasal degeneration","volume":"80","author":"Armstrong","year":"2013","journal-title":"Neurology"},{"key":"R32-20250630","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"R33-20250630","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: a frontal assessment battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"key":"R35-20250630","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"R36-20250630","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/brain\/awm032","article-title":"A clinical rating scale for progressive supranuclear palsy","volume":"130","author":"Golbe","year":"2007","journal-title":"Brain"},{"key":"R37-20250630","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jcomdis.2014.06.008","article-title":"The Apraxia of Speech Rating Scale: a tool for diagnosis and description of apraxia of speech","volume":"51","author":"Strand","year":"2014","journal-title":"J Commun Disord"},{"key":"R38-20250630","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bandl.2018.06.004","article-title":"Prosodic and phonetic subtypes of primary progressive apraxia of speech","volume":"184","author":"Utianski","year":"2018","journal-title":"Brain Lang"},{"key":"R39-20250630","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/arclin\/14.6.481","article-title":"An empirically derived short form of the Boston naming test","volume":"14","author":"Lansing","year":"1999","journal-title":"Arch Clin Neuropsychol"},{"key":"R40-20250630","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1212\/WNL.0000000000000412","article-title":"Nonverbal oral apraxia in primary progressive aphasia and apraxia of speech","volume":"82","author":"Botha","year":"2014","journal-title":"Neurology"},{"key":"R41-20250630","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/gps.4756","article-title":"A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores","volume":"33","author":"Carson","year":"2018","journal-title":"Int J Geriatr Psychiatry"},{"key":"R42-20250630","first-page":"792","article-title":"The Mayo Clinic Adult Lifespan Template: better quantification across the lifespan","volume":"13","author":"Schwarz","year":"2017","journal-title":"Alzheimers Dement"},{"key":"R43-20250630","doi-asserted-by":"crossref","first-page":"120509","DOI":"10.1016\/j.neuroimage.2024.120509","article-title":"Direct comparison between (18)F-Flortaucipir tau PET and quantitative susceptibility mapping in progressive supranuclear palsy","volume":"286","author":"Satoh","year":"2024","journal-title":"Neuroimage"},{"key":"R44-20250630","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/mds.26834","article-title":"[(18) F]AV-1451 tau positron emission tomography in progressive supranuclear palsy","volume":"32","author":"Whitwell","year":"2017","journal-title":"Mov Disord"},{"key":"R45-20250630","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cortex.2017.12.021","article-title":"Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech","volume":"99","author":"Utianski","year":"2018","journal-title":"Cortex"},{"key":"R46-20250630","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2967\/jnumed.114.146027","article-title":"Cerebellum can serve as a pseudo-reference region in Alzheimer disease to detect neuroinflammation measured with PET radioligand binding to translocator protein","volume":"56","author":"Lyoo","year":"2015","journal-title":"J Nucl Med"},{"key":"R47-20250630","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1212\/NXI.0000000000000984","article-title":"Microglia activation in basal ganglia is a late event in huntington disease pathophysiology","volume":"8","author":"Rocha","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R48-20250630","doi-asserted-by":"crossref","first-page":"e081801","DOI":"10.1002\/alz.081801","article-title":"Validating noninvasive techniques for 11C-ER176 PET quantification in controls and Alzheimer\u2019s disease patients","volume":"19","author":"Rossano","year":"2023","journal-title":"Alzheimers Dementia"},{"key":"R49-20250630","doi-asserted-by":"crossref","first-page":"103394","DOI":"10.1016\/j.nicl.2023.103394","article-title":"Spatial patterns of elevated magnetic susceptibility in progressive apraxia of speech","volume":"38","author":"Satoh","year":"2023","journal-title":"Neuroimage Clin"},{"key":"R50-20250630","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s40478-016-0315-6","article-title":"An autoradiographic evaluation of AV-1451 Tau PET in dementia","volume":"4","author":"Lowe","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"R52-20250630","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/1742-2094-9-232","article-title":"Evaluation of age-related changes in translocator protein (TSPO) in human brain using (11)C-[R]-PK11195 PET","volume":"9","author":"Kumar","year":"2012","journal-title":"J Neuroinflammation"},{"key":"R53-20250630","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.neuroimage.2017.05.015","article-title":"Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity","volume":"170","author":"Ewert","year":"2018","journal-title":"Neuroimage"},{"key":"R54-20250630","first-page":"2053","article-title":"Comparative evaluation of MR-based partial-volume correction schemes for PET","volume":"40","author":"Meltzer","year":"1999","journal-title":"J Nucl Med"},{"key":"R55-20250630","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"key":"R56-20250630","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jalz.2018.02.020","article-title":"Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer\u2019s disease","volume":"14","author":"Whitwell","year":"2018","journal-title":"Alzheimers Dement"},{"key":"R57-20250630","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3389\/fninf.2016.00020","article-title":"VoxelStats: A MATLAB package for multi-modal voxel-wise brain image analysis","volume":"10","author":"Mathotaarachchi","year":"2016","journal-title":"Front Neuroinform"},{"key":"R58-20250630","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/jnen\/60.6.647","article-title":"Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration","volume":"60","author":"Ishizawa","year":"2001","journal-title":"J Neuropathol Exp Neurol"},{"key":"R59-20250630","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bandl.2013.02.005","article-title":"Distinct regional anatomic and functional correlates of neurodegenerative apraxia of speech and aphasia: an MRI and FDG-PET study","volume":"125","author":"Whitwell","year":"2013","journal-title":"Brain Lang"},{"key":"R60-20250630","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jnnp-2020-325549","article-title":"Neuroinflammation predicts disease progression in progressive supranuclear palsy","volume":"92","author":"Malpetti","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R61-20250630","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1093\/brain\/awad078","article-title":"Microglial activation in the frontal cortex predicts cognitive decline in frontotemporal dementia","volume":"146","author":"Malpetti","year":"2023","journal-title":"Brain"},{"key":"R62-20250630","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/brain\/awad322","article-title":"Neuroinflammation is linked to dementia risk in Parkinson\u2019s disease","volume":"147","author":"Kouli","year":"2024","journal-title":"Brain"},{"key":"R63-20250630","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/j.neurobiolaging.2012.12.002","article-title":"White matter tract signatures of the progressive aphasias","volume":"34","author":"Mahoney","year":"2013","journal-title":"Neurobiol Aging"},{"issue":"suppl 2","key":"R64-20250630","doi-asserted-by":"crossref","first-page":"Ii6","DOI":"10.1007\/BF03161076","article-title":"Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration","volume":"246","author":"Dickson","year":"1999","journal-title":"J Neurol"},{"key":"R65-20250630","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","article-title":"Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes","volume":"9","author":"Kwon","year":"2020","journal-title":"Transl Neurodegener"},{"key":"R66-20250630","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0896-6273(00)80194-4","article-title":"GFAP is necessary for the integrity of CNS white matter architecture and long-term maintenance of myelination","volume":"17","author":"Liedtke","year":"1996","journal-title":"Neuron"},{"key":"R67-20250630","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ana.24844","article-title":"Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies","volume":"81","author":"Marquie","year":"2017","journal-title":"Ann Neurol"},{"key":"R68-20250630","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/mds.27271","article-title":"The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases","volume":"33","author":"Vermeiren","year":"2018","journal-title":"Mov Disord"},{"key":"R69-20250630","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1007\/s00259-022-05822-9","article-title":"Monoamine oxidase binding not expected to significantly affect [(18)F]flortaucipir PET interpretation","volume":"49","author":"Wright","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R70-20250630","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2967\/jnumed.117.195248","article-title":"Off-target (18)F-AV-1451 binding in the basal ganglia correlates with age-related iron accumulation","volume":"59","author":"Choi","year":"2018","journal-title":"J Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:01:38Z","timestamp":1751299298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":68,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005962","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"2024-11-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}